GSK press releases Follow GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer ADC complements GSK’s diverse pipeline in prostate cancer anchored by GSK’227, a B7H3-targeted ADC. https://www.gsk.com/en-gb/media/press-releases/gsk-acquires-exclusive-rights-from-syndivia-for-antibody-drug-conjugate/ gsk.com
